Lentigen Technology, Inc.
15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jun 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 20, 2026The maintenance fee for Compositions and Methods for Treating Cancer with ANTI-CD19/CD20 Immunotherapy (US 11,680,103) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Mar 24, 2027The maintenance fee for Chimeric antigen receptors and methods of use (US 10,421,810) comes due Mar 24, 2027. Unpaid by Sep 24, 2027, it lapses early.
- 2 fees due Apr 15 to 30, 2027 · next Apr 15
- 1 fee due Aug 20, 2027The maintenance fee for Chimeric antigen receptors and methods of use (US 11,905,515) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Compositions and Methods for Treating Cancer with Self-Driving Chimeric Antigen Receptors (US 11,969,443) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Method to Treat Cancer with Engineered T-Cells (US 10,639,329) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,639,329 | Method to Treat Cancer with Engineered T-Cells In force · High confidence | In force | High confidence | |
| US 10,421,810 | Chimeric antigen receptors and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,689,431 | Compositions and Methods for Treating Cancer with DuoCARs In force · High confidence | In force | High confidence | |
| US 11,208,455 | Compositions and Methods for Treating Cancer with DuoCARs In force · Medium confidence | In force | Medium confidence | |
| US 11,453,712 | Compositions and Methods for Treating Cancer with DuoCARs In force · High confidence | In force | High confidence | |
| US 11,802,142 | Compositions and Methods for Treating Cancer with DuoCARs In force · High confidence | In force | High confidence | |
| US 12,365,718 | Compositions and Methods for Treating Cancer with DuoCARs In force · Low confidence | In force | Low confidence | |
| US 12,790,382 | Compositions and Methods for Treating Cancer with DuoCARs In force · High confidence | In force | High confidence | |
| US 12,714,750 | Compositions and Methods for Treating Cancer with Anti-CD33 Immunotherapy In force · High confidence | In force | High confidence | |
| US 11,905,515 | Chimeric antigen receptors and methods of use In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 27: 15 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 1 no status recorded